Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Poziotinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 20/20 | 0.98 |
| ▸ | ERBB2 known ✓ | P04626 | 5/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.98 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.98 |
| ▸ | RET | P07949 | 1/20 | 0.98 |
| ▸ | MET | P08581 | 1/20 | 0.98 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.98 |
| ▸ | TEC | P42680 | 1/20 | 0.98 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.98 |
| ▸ | EPHA4 | P54764 | 1/20 | 0.98 |
| ▸ | BTK | Q06187 | 1/20 | 0.98 |
| ▸ | TNK1 | Q13470 | 1/20 | 0.98 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Poziotinib SCHEMBL3391764 | 0.99 | EGFR (1.00) | EGFRERBB2KCNH2RIPK2RET | |
| Poziotinib SCHEMBL29453260 | 0.99 | EGFR (1.00) | EGFRERBB2KCNH2RIPK2RET | |
| Poziotinib SCHEMBL29375341 | 0.99 | EGFR (1.00) | EGFRERBB2KCNH2RIPK2RET | |
| SCHEMBL22598558 | 0.95 | EGFR (1.00) | EGFRERBB2KCNH2RIPK2RET | |
| SCHEMBL29751974 | 0.95 | EGFR (1.00) | EGFRERBB2KCNH2RIPK2RET | |
| SCHEMBL3390837 | 0.95 | EGFR (1.00) | EGFRERBB2KCNH2RIPK2RET | |
| SCHEMBL14786610 | 0.93 | EGFR (0.88) | EGFRERBB2KCNH2RIPK2RET | |
| SCHEMBL3391925 | 0.93 | EGFR (1.00) | EGFRERBB2KCNH2RIPK2RET | |
| SCHEMBL21613670 | 0.92 | EGFR (0.87) | EGFRERBB2KCNH2RIPK2RET | |
| SCHEMBL29444156 | 0.92 | EGFR (1.00) | EGFRERBB2KCNH2RIPK2RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12629375-B2 | Compounds with anti-tumor activity against cancer cells bearing HER2 exon 21 insertions | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-05-19 | — | — | US | claimed |
| US-20250312348-A1 | COMPOUNDS WITH ANTI-TUMOR ACTIVITY AGAINST CANCER CELLS BEARING EGFR OR HER2 EXON 20 INSERTIONS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-10-09 | — | — | US | claimed |
| WO-2023015149-A1 | TREATMENT OF NON-SMALL CELL LUNG CANCER WITH POZIOTINIB | SPECTRUM PHARMACEUTICALS, INC. (US) | 2023-02-09 | — | — | WO | claimed |
| US-20220175779-A1 | COMPOUNDS AGAINST CANCER BEARING TYROSINE KINASE INHIBITOR RESISTANT EGFR MUTATIONS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-06-09 | — | — | US | claimed |
| US-20220175778-A1 | COMPOUNDS WITH ANTI-TUMOR ACTIVITY AGAINST CANCER CELLS BEARING HER2 EXON 21 INSERTIONS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-06-09 | — | — | US | claimed |
| US-20220143023-A1 | COMPOUNDS WITH ANTI-TUMOR ACTIVITY AGAINST CANCER CELLS BEARING EGFR OR HER2 EXON 20 INSERTIONS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-05-12 | — | — | US | claimed |
| EP-3956035-A1 | COMPOUNDS AGAINST CANCER BEARING TYROSINE KINASE INHIBITOR RESISTANT EGFR MUTATIONS | Board of Regents, The University of Texas System (US) | 2022-02-23 | — | — | EP | claimed |
| US-20220041751-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-02-10 | — | — | US | claimed |
| EP-3946293-A1 | COMPOUNDS WITH ANTI-TUMOR ACTIVITY AGAINST CANCER CELLS BEARING EGFR OR HER2 EXON 20 INSERTIONS | Board of Regents, The University of Texas System (US) | 2022-02-09 | — | — | EP | claimed |
| EP-3946632-A1 | COMPOUNDS WITH ANTI-TUMOR ACTIVITY AGAINST CANCER CELLS BEARING HER2 EXON 21 INSERTIONS | Board of Regents, The University of Texas System (US) | 2022-02-09 | — | — | EP | claimed |
| EP-2763981-B1 | METHOD FOR PREPARING 1-(4-(4-(3,4-DICHLORO-2-FLUOROPHENYLAMINO)-7-METHOXYQUINAZOLIN-6-YLOXY)PIPERIDIN-1-YL)-PROP-2-EN-1-ONE HYDROCHLORIDE AND INTERMEDIATES USED THEREIN | HANMI SCIENCE CO LTD (KR) | 2020-01-08 | — | — | EP | claimed |
| US-8859767-B2 | Method for preparing 1-(4-(4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)-prop-2-en-1-one hydrochloride and intermediates used therein | HANMI SCIENCE CO., LTD (KR) | 2014-10-14 | — | — | US | claimed |
| US-20140275534-A1 | METHOD FOR PREPARING 1-(4-(4-(3,4-DICHLORO-2-FLUOROPHENYLAMINO)-7-METHOXYQUINAZOLIN-6-YLOXY) PIPERIDIN-1-YL)-PROP-2-EN-1-ONE HYDROCHLORIDE AND INTERMEDIATES USED THEREIN | HANMI SCIENCE CO., LTD. (KR) | 2014-09-18 | — | — | US | claimed |
| EP-2763981-A2 | METHOD FOR PREPARING 1-(4-(4-(3,4-DICHLORO-2-FLUOROPHENYLAMINO)-7-METHOXYQUINAZOLIN-6-YLOXY)PIPERIDIN-1-YL)-PROP-2-EN-1-ONE HYDROCHLORIDE AND INTERMEDIATES USED THEREIN | Hanmi Science Co., Ltd. (KR) | 2014-08-13 | — | — | EP | claimed |
| WO-2013051883-A2 | METHOD FOR PREPARING 1-(4-(4-(3,4-DICHLORO-2-FLUOROPHENYLAMINO)-7-METHOXYQUINAZOLIN-6-YLOXY)PIPERIDIN-1-YL)-PROP-2-EN-1-ONE HYDROCHLORIDE AND INTERMEDIATES USED THEREIN | HANMI SCIENCE CO., LTD. (KR) | 2013-04-11 | — | — | WO | claimed |
| US-12629375-B2 | Compounds with anti-tumor activity against cancer cells bearing HER2 exon 21 insertions | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-05-19 | — | — | US | disclosed |
| WO-2025238176-A1 | COMBINATIONS OF EGFR/ERB AND BET INHIBITORS FOR GASTRIC CANCER | GENOME RESEARCH LIMITED (GB) | 2025-11-20 | — | — | WO | disclosed |
| WO-2013051883-A3 | METHOD FOR PREPARING 1-(4-(4-(3,4-DICHLORO-2-FLUOROPHENYLAMINO)-7-METHOXYQUINAZOLIN-6-YLOXY)PIPERIDIN-1-YL)-PROP-2-EN-1-ONE HYDROCHLORIDE AND INTERMEDIATES USED THEREIN | HANMI SCIENCE CO., LTD. (KR) | 2013-06-06 | — | — | WO | disclosed |
| WO-2013051883-A2 | METHOD FOR PREPARING 1-(4-(4-(3,4-DICHLORO-2-FLUOROPHENYLAMINO)-7-METHOXYQUINAZOLIN-6-YLOXY)PIPERIDIN-1-YL)-PROP-2-EN-1-ONE HYDROCHLORIDE AND INTERMEDIATES USED THEREIN | HANMI SCIENCE CO., LTD. (KR) | 2013-04-11 | — | — | WO | disclosed |
| WO-2013051883-A2 | METHOD FOR PREPARING 1-(4-(4-(3,4-DICHLORO-2-FLUOROPHENYLAMINO)-7-METHOXYQUINAZOLIN-6-YLOXY)PIPERIDIN-1-YL)-PROP-2-EN-1-ONE HYDROCHLORIDE AND INTERMEDIATES USED THEREIN | HANMI SCIENCE CO., LTD. (KR) | 2013-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12629375-B2 | Compounds with anti-tumor activity against cancer cells bearing HER2 exon 21 insertions | ERBB2, ERBB3, EGFR | EGFR 3/4885ERBB2 1/4885KCNH2 3728/4885 |
| US-20140275534-A1 | METHOD FOR PREPARING 1-(4-(4-(3,4-DICHLORO-2-FLUOROPHENYLAMINO)-7-METHOXYQUINAZOLIN-6-YLOXY) PIPERIDIN-1-YL)-PROP-2-EN-1-ONE HYDROCHLORIDE AND INTERMEDIATES USED THEREIN | EGFR, ERBB2, ERBB3 | EGFR 1/4885ERBB2 2/4885KCNH2 3013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.